This clinical trial is focused on studying the long-term safety and effectiveness of a treatment called ligelizumab for individuals with food allergy. Food allergy is a condition where certain foods trigger an abnormal immune response, leading to symptoms that can range from mild to severe. The study aims to understand how well ligelizumab works over an extended period and how safe it is for patients who have already participated in previous studies involving this treatment.

Participants in this study will receive ligelizumab, which is administered as a solution for injection. The study will also include a comparison with a placebo to evaluate the treatment’s effects. Additionally, some participants may receive other medications such as salbutamol, which is used for inhalation, and epinephrine, which is given as an injection. Another treatment being studied is PCM001, which is a granule form for oral suspension made from defatted peanut powder. These treatments are part of the study to assess their role in managing food allergies.

The study will take place over several years, during which participants will attend regular visits to receive their treatments and undergo assessments. These assessments will help researchers gather information on how well the treatments are tolerated and their impact on food allergy symptoms. The goal is to provide valuable insights into the long-term management of food allergies using ligelizumab and other related treatments.